The average product development period for the novel therapeutics is about 10-15 years , so we are just in the cusp of witnessing more product approvals soon in India . We will see at least five new products on the shelves in the next two to three years ’ time
product to be approved by a regulatory body , anywhere in the worldothers being Cartistem ( Korea ), Prochymal ( Canada ), Temcell ( Japan ).
With Stempeucel ® declared as new drug by the regulatory body for treating CLI - > Stempeucel ® injection will be covered under medical insurance . Also , the drug will be eligible for exports . We are looking for a strategic pharma partner in India to market the product for CLI treatment in 2017 . Stempeutics uses a novel patented technology in the manufacture of Stempeucel ® that has many advantages over other stem cell based products .
Stempeutics has also published Phase 1 data in Journal of Translational Medicine , Phase 2 data in Stem Cell Translational Medicine and CLI potency paper in Stem Cell Research Therapy journal .
Please tell us about the latest activities in terms of new research and product development at Stempeutics ?
Stempuetics is working on two more innovative products . The second innovative product being developed by is Stempeucare ® range of cosmetics . It is developed from adult stem cells derived Growth Factors / Cytokines cocktail for various derma applications including rejuvenation of aging skin , hair fall control and hair growth , under eye cream etc . First product which has gone to the market is an intensive firming skin care cosmetic product , branded as Cutisera™ . Cutisera™ product has 5 distinct benefits i . e . ( 1 ) reduction of lines and wrinkles ( 2 ) lightning of dark spots ( 3 ) evenness of skin tone ( 4 ) improvement in skin firmness ( 5 ) improvement in skin hydration . It has been launched in India through partnership with Cipla in January , 2016 .
Other products in the pipe
BIOVOICENEWS . COM 43